Skip to main content
Affiliate disclosureWe earn a commission if you buy through links on this page, at no extra cost to you. Read our methodology →
CholinergicClinical dose · 300–600mg/day (the positive Alzheimer's trial used 1200mg/day)Onset · Acute effects at 60 minutes in one RCT; the Alzheimer's trial measured benefit at 90 and 180 days

Alpha-GPC

A multicenter RCT in mild-to-moderate Alzheimer's dementia (De Jesus Moreno, 2003, n=261) found 1200mg/day improved ADAS-Cog, MMSE and global scores versus placebo at 90 and 180 days, and a 2023 meta-analysis supports benefit in cerebrovascular cognitive impairment. In healthy men, a single 315–630mg dose improved Stroop performance but not N-Back or Flanker (Kerksick 2024). Sports trials are inconsistent: a lower-body force gain after 6 days at 600mg (Bellar 2015), no strength effect at 250–500mg for 7 days, and no power-output effect after a single 630mg dose.

By The Nootropic Lab editorial teamUpdated 8 min read✓ Fact-checked

Evidence reviewed:

Mechanism of action

Alpha-GPC (alpha-glycerylphosphorylcholine) is the most bioavailable choline precursor. It delivers choline directly across the blood-brain barrier, where it is used to synthesise acetylcholine. It also supports cell membrane phospholipid synthesis. It is often marketed for growth hormone release, but a 2024 RCT at 630mg found no growth hormone difference versus placebo.

Clinical evidence summary

A multicenter RCT in mild-to-moderate Alzheimer's dementia (De Jesus Moreno, 2003, n=261) found 1200mg/day improved ADAS-Cog, MMSE and global scores versus placebo at 90 and 180 days, and a 2023 meta-analysis supports benefit in cerebrovascular cognitive impairment. In healthy men, a single 315–630mg dose improved Stroop performance but not N-Back or Flanker (Kerksick 2024). Sports trials are inconsistent: a lower-body force gain after 6 days at 600mg (Bellar 2015), no strength effect at 250–500mg for 7 days, and no power-output effect after a single 630mg dose.

Human effect matrix

Based on human clinical trials only. Animal and in-vitro data excluded.

EffectEvidenceMagnitudeStudies
Acetylcholine Synthesis strong
Large
2
Memory & Cognition moderate
Moderate
2
Athletic Power Output mixed
Small
3
Neuroprotection moderate
Moderate
2

Evidence key: Strong = multiple consistent RCTs · Moderate = smaller/fewer RCTs · Preliminary = early trials or small n · Mixed = conflicting results

Documented benefits

  • Cognition in Alzheimer's and cerebrovascular dementia (1200mg/day)
  • Acute Stroop (executive) performance in healthy men
  • Raises plasma choline

Side effects & cautions

  • Well tolerated
  • Headache if combined with other cholinergics
  • 500mg/day significantly suppressed serum TSH (thyroid-stimulating hormone) in a 7-day trial

How to take

Dosage300–600mg/day — matches the healthy-adult and sports trials; the strongest (Alzheimer's) evidence used 1200mg/day
TimingMorning or 30–60 minutes before a demanding cognitive task or workout
With foodCan be taken with or without food. Slightly better absorbed with a small meal. Do not take late in the day — the acetylcholine activation can interfere with sleep.
FormsCapsule (common), powder. Alpha-GPC is hygroscopic (absorbs moisture from air) — powder can become sticky; capsule form is more practical. 50% and 85% concentration forms exist; the 50% form (more common) doubles the serving size but is equivalent in active dose.

Stacking recommendations

Ingredients that pair well with Alpha-GPC and why.

Alpha-GPC provides immediate acetylcholine support; Lion's Mane drives long-term NGF synthesis. Neither overlaps mechanistically — a clean acute + long-term pairing.

Alpha-GPC handles acute memory encoding via acetylcholine; Bacopa handles memory consolidation and storage. Together they cover both encoding and consolidation stages of memory formation.

Huperzine A prevents acetylcholine breakdown while Alpha-GPC increases acetylcholine synthesis. Powerful combination in theory — but use with caution and low doses, as cholinergic overload (nausea, headache, muscle cramps) is a real risk. Not recommended without experience.

Frequently asked questions

Alpha-GPC vs Citicoline — which is better for focus?

Both are excellent. Alpha-GPC has a slight edge for acute cholinergic effects and is preferred for workout performance. Citicoline also provides cytidine (uridine precursor), giving it a broader neuroprotective profile. For pure focus and acetylcholine, Alpha-GPC wins slightly; for comprehensive brain health support, Citicoline is more complete. Don't stack them together — you'll get too much choline activity.

Is it safe to combine Alpha-GPC with Huperzine A?

Use caution. Both increase acetylcholine (Alpha-GPC via synthesis, Huperzine A via inhibiting breakdown). The combination is potent and can cause cholinergic overstimulation — symptoms include nausea, headache, excessive salivation, and muscle cramps. If combining, use lower doses of each (e.g. 200mg Alpha-GPC + 50mcg Huperzine A) and do not take daily.

Why does Alpha-GPC powder go sticky?

Alpha-GPC is highly hygroscopic — it absorbs water from the air quickly. This is normal and doesn't affect potency. Store in an airtight container in a cool, dry place. Capsule form avoids this problem entirely.

Is there a cardiovascular risk with Alpha-GPC?

Unresolved. The CARDIA cohort study (published 2024) linked higher plasma choline — not alpha-GPC supplements — with incident cardiovascular disease, while a meta-analysis of dietary choline intake found no association. No study has tested alpha-GPC supplementation directly for cardiovascular outcomes. If you have cardiovascular disease, discuss it with your doctor.

Top stacks containing Alpha-GPC

Alpha-GPC in Southeast Asia

Alpha-GPC (choline alfoscerate) is not named specifically in the BPOM, NPRA and ASEAN documents cited below, nor in the ASEAN negative-list guidance document cited below. Because it is not separately listed, each market's general ingredient-safety and product-registration framework applies rather than an alpha-GPC-specific rule. Indonesia's BPOM, for example, requires health-supplement raw materials to meet its own pharmacopoeia standard or, failing that, a named alternative reference; Malaysia's NPRA checks new active ingredients against safety and dosage documentation rather than a fixed list.

The general-rule pathway for alpha-GPC

Indonesia's BPOM Regulation No. 24 of 2023 requires that the safety and quality requirements for a health-supplement raw material "harus sesuai dengan ketentuan dalam farmakope Indonesia dan/atau farmakope herbal Indonesia" (must conform to the provisions of the Indonesian Pharmacopoeia and/or Indonesian Herbal Pharmacopoeia). Where the raw material is not covered there, the regulation allows reference to materia medika Indonesia; … farmakope Amerika Serikat, farmakope Inggris, atau farmakope negara lain; dan/atau … kompendium/standar internasional, referensi ilmiah yang diakui (Indonesian materia medica; US, British or other national pharmacopoeias; and/or international compendia and recognised scientific references). Malaysia's NPRA guideline similarly asks that documentation for a new active ingredient "support the safety use and dose of new active ingredients as a health supplement."

Products in Southeast Asia

HSA / NPRA / BPOM / FDA PH / Thai FDA

Does Indonesia's BPOM name alpha-GPC on a specific ingredient list?

A specific BPOM listing for alpha-GPC (choline alfoscerate) was not found. BPOM Regulation No. 24 of 2023 instead sets the general standard that a health-supplement raw material's safety and quality requirements "harus sesuai dengan ketentuan dalam farmakope Indonesia dan/atau farmakope herbal Indonesia," with recognised pharmacopoeias, materia medica or scientific references as fallback standards when the material is not covered there.

How does Malaysia's NPRA treat an ingredient like alpha-GPC that isn't pre-listed?

NPRA's health-supplement registration guideline states that "listed active ingredients can be checked trough http://npra.moh.gov.my/ of product search," and for an ingredient submitted as new to a formulation, "the documentation must support the safety use and dose of new active ingredients as a health supplement" — a dossier-based route rather than a pre-published ingredient list.

Sources: BPOM — Peraturan BPOM No. 24 Tahun 2023 tentang Persyaratan Keamanan dan Mutu Suplemen Kesehatan · BPOM — Peraturan BPOM No. 24 Tahun 2023 tentang Persyaratan Keamanan dan Mutu Suplemen Kesehatan · NPRA — Drug Registration Guidance Document, Appendix 4: Guideline on Registration of Health Supplements · NPRA — Drug Registration Guidance Document, Appendix 4: Guideline on Registration of Health Supplements · HSA — Guidelines on Prohibited and Restricted Ingredients in Health Supplements and Traditional Medicines (Oct 2025) · ASEAN — Guiding Principles for Inclusion into or Exclusion from the Negative List of Substances for Health Supplements

Regulatory note

Health supplements in Singapore are regulated by the Health Sciences Authority (HSA); in Malaysia by the National Pharmaceutical Regulatory Agency (NPRA); in Indonesia by the Badan Pengawas Obat dan Makanan (BPOM); in the Philippines by FDA Philippines; in Thailand by FDA Thailand. Halal certification is required by law for supplements marketed to Indonesian consumers from 18 October 2026, regulated by the Badan Penyelenggara Jaminan Produk Halal (BPJPH); in Malaysia, products described as halal must be certified, with the Jabatan Kemajuan Islam Malaysia (JAKIM) as the certifying body. We surface certification status per product where verifiable. This page is editorial, not medical advice. Consult a qualified healthcare professional before starting any supplement.

Sources (7)expand